Navigation Links
Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
Date:7/6/2008

atients with advanced NSCLC were randomized to the comparator arm; 191 were randomized to the OPAXIO arm with a dosage of 175 mg/m^2, and 96 were randomized to the OPAXIO arm at a dosage of 235 mg/m^2. The OPAXIO dose was reduced to 175 mg/m^2 after 96 patients had been treated, because the Data Monitoring Committee noted an increase in deaths associated with neutropenia in patients who had received the 235 mg/m^2 dosage. The following data refers to those patients treated at the OPAXIO dose of 175 mg/m^2. The median number of cycles administered was 4, with a median of 3.5 in the control arm. A total of 754 cycles of OPAXIO were administered, and 652 cycles were administered in the comparator arm. More patients in the OPAXIO arm received 6 cycles of treatment (38 percent versus 23 percent; p = 0.002). Progressive disease was the most common reason for not completing 6 cycles (55 percent in the OPAXIO arm and 59 percent in the comparator arm). Fewer OPAXIO patients (12 percent) discontinued treatment as a result of adverse events, compared to 17 percent of patients in the control arm. Survival, time to progression (TTP), and response rates were similar in both arms. Median overall survival was 7.3 months in the OPAXIO arm and 6.6 months in the control arm. The estimated 1-year survival rate was the same in both arms (26 percent), and the approximate 2-year survival rate was numerically higher in the OPAXIO arm (15 percent) than the comparator arm (10 percent). There was a lower requirement for red blood cell transfusions (p = 0.001), erythropoietin use (p = 0.014), myeloid growth factors (p = 0.032), and new narcotic analgesics (p = 0.034) in the OPAXIO arm when compared to the control arm. No significant differences were evident in quality of life based on FACT-LCS evaluations between the two arms. OPAXIO patients experienced fewer hematologic (p <0.001) and gastrointestinal (p = 0.004) adverse events. Neuropathy occurred more frequently in the OPAXIO arm compared
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles
2. Genzyme and Isis Complete Licensing of Mipomersen
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
5. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
6. Pharmaxis Long-Term Safety Study of Bronchitol Completes
7. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
8. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
9. Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkins Lymphoma
10. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
11. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 /PRNewswire/ - Anything Technologies Media, Inc. (OTC:EXMT) has ... Garden Solutions (FIGS), www.frontiergarden.com has been ... Project Manager for a My Compassion originated medical ... located in Alaska.  The project will be funded ... Teaming Partners. The first phase of the project, ...
(Date:7/30/2015)... 30, 2015  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... and webcast at 5:00 p.m. Eastern Time (2:00 p.m. ... second quarter 2015 financial results and provide a corporate ... NASDAQ Global Select Market closes that day. ... for domestic callers and 914.495.8552 for international callers. Please ...
(Date:7/30/2015)...  Alimera Sciences, Inc. (NASDAQ: ALIM ) (Alimera), ... and commercialization of prescription ophthalmic pharmaceuticals, today announced that ... financial results after the market close on Monday, August ... the same day at 4:30 p.m. ET. ... Officer, and Rick Eiswirth , Chief Operating Officer ...
Breaking Medicine Technology:Frontier Indoor Garden Solutions announced as Horticultural Supplier and Project Manager for Alaskan Tribal Medical Marijuana Grow Facility 2Frontier Indoor Garden Solutions announced as Horticultural Supplier and Project Manager for Alaskan Tribal Medical Marijuana Grow Facility 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 4Alimera Sciences To Release Second Quarter Fiscal Year 2015 Financial Results 2
(Date:7/30/2015)... FL (PRWEB) , ... July 30, 2015 , ... Using ... eradicate suicide and teach people more effective ways to prevent and manage major depression. ... to react fast enough, so people fall through the cracks and die needlessly everyday,” ...
(Date:7/30/2015)... ... July 30, 2015 , ... Between 2012 and 2014 ... Health News Florida on June 17th. Those untreated heroin use disorders share ... prevent the spread of dirty needles throughout the community. Ultimately Florida’s HIV infection rates ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... (DEA) Acting Administrator Chuck Rosenberg’s announcement of the reinstitution of National Prescription Drug ... September 26, 2015 from 10:00 AM to 2:00 PM local time. On the ...
(Date:7/30/2015)... ... July 30, 2015 , ... InventHelp, a leading inventor service ... personal-care device that makes it easy to apply lotion or medication to a hard-to-reach ... assistance when applying lotion or medication to the back, and provides thorough coverage. The ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... at multinational organizations and NGO’s, according to a new survey by leading international ... that property damage and employee medical expenses represented the largest sources of financial ...
Breaking Medicine News(10 mins):Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 2Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 3Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:InventHelp® Client Patents “My Back Buddy” – Device Could Apply Lotion to Hard-to-Reach Areas Easily 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3
... Warwick have discovered high doses of thiamine vitamin B1 ... , Kidney disease, or diabetic nephropathy, develops progressively in patients ... assessed by a high excretion rate of the protein albumin ... The research is led by Dr Naila Rabbani and Professor ...
... one of seven centers to receive a four-year grant ... cutting edge genomic technologies to better understand lung disease. ... study to probe the causes of chronic obstructive pulmonary ... characterized by airflow limitation. , COPD is the ...
... Texas, Dec. 8 LifeCare Holdings, Inc., today,announced the ... marketing,for the 20-hospital long term acute care hospital system. ... , A proven ... management experience to LifeCare, including experience in senior,marketing, business ...
... should not determine whether an older patient with acute ... cell transplant from a matched donor, researchers of the ... today at the 50th annual meeting of the American ... just as well as younger patients with transplants that ...
... generic prescriptions from Jan 1 - June 30, 2009; BCBSNC,s 2008 "Medication ... total of $13 million on out-of-pocket costs; The 2009 generic copay waiver ... ... NC (Vocus) December 8, 2008 -- Blue Cross and Blue Shield ...
... Dec. 8 /PRNewswire/ - CHOC Children,s, a regional pediatric ... Orange, California facility on its newly commissioned RIVA (Robotic ... IV syringes and bags, is manufactured by Intelligent Hospital ... Vice President of Sales and Marketing for IH Systems, ...
Cached Medicine News:Health News:Vitamin B1 could reverse early-stage kidney disease in diabetes patients 2Health News:Boston University School of Medicine receives a grant to study chronic obstructive pulmonary disease 2Health News:Older age doesn't affect survival after bone marrow transplant 2Health News:BCBSNC Helps Customers Fight Recession With Free Generics 2Health News:BCBSNC Helps Customers Fight Recession With Free Generics 3Health News:BCBSNC Helps Customers Fight Recession With Free Generics 4Health News:CHOC Children's Draws First Patient Dose With RIVA System 2
... new Oculus Easygraph is a corneal ... tools you need for refractive surgery, ... therapy contact lens fitting in a ... 4" package. All you need to ...
The only ergonomic work station of its kind with an optional built-in keratograph and flat-screen. The Concepta is a modern workstation for the examination and refraction of patients....
The natural look of 3 in 1 technology in virtually any prescription....
Dot matrix pattern for light eyed patients....
Medicine Products: